Medicsight Share Discussion Threads

[paxman] 20/5/2011 09:09

A Medicsight 2008 presentation estimated 350,000 CT scanner linked workstations worldwide.

Each 1,000 workstations signed up gives them yearly revenue of over $4m.

If they get 5% of the worldwide market they get $70 m of yearly revenue on the above estimates.

That must be why one of the brokers was estimating EPS of 17.5p within 2 years of regulatory approval in US and Japan.

[mak600] 20/5/2011 09:08

i should add of course, there may well be a very long list of stale bulls from the £1.10 level though...!

[shifter2] 20/5/2011 09:07

mak600

hold mgt stock hoping for windfall of mdst at some point traded over 1 million yesterday in US

luck to the brave

[mak600] 20/5/2011 09:05

ah, and one other thing - 55% shareholder in MDST is a US holding company traded on the AMEX exchange. Hence 1) the US will know this stock and 2) I thought i'd try and buy some but the liquidity was showing an average daily volume of about 26000 and a then price of 23 cents. So, effectively impossible to buy in size.

edit: MGT Capital Investments is the name...

[mak600] 20/5/2011 08:59

i added at 8.52 this morning, bought a load at 5.35 and 5.5 yesterday as a quick punt. Having read up last night though i'm staying put for a bit. From a purely technical view this could go through the roof, since the fund raising at the £1.10 level and 2007 IPO i can't see any further fundraising? So no long list of stale bulls at variously diminishing share price levels that often blight forgotten companies that suddenly come good. Technically, rather significant :)

[adorling] 20/5/2011 08:18

I'm in for 250,000 this morning at 9.3p and 10.03p - might see some retrace with small shares but I am looking for 50% growth within next 6 months as I am sure partnership deals will be forthcoming for sales promotion in US and commercial deals for Japan. Directors will be very motivated to see momentum in the share price continue.

[ukmassy] 20/5/2011 08:02

Auction 9/8.885. At least 15p today?

[crosswire] 20/5/2011 07:42

7:03 am
The Times

Deal of the day: Medicsight soared 140% to 8.1p, after American regulators gave approval for its most important product to be sold there. The AIM Company's computer-aided detection software helps to diagnose colon cancer. In 2007 the prospect of U.S. clearance for Medicsight's ColonCAD was the driving force behind its stock market flotation.

[paxman] 19/5/2011 21:55

Directors bought shares at 42p back in Aug 2008 expecting FDA approval.

Well now they've got it.

Let's hope they make money on their investment. They should know better than most.

Medicsight (AIM:MDST), industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and diagnosis of disease, has today been notified that on 11 August 2008, Executive Directors Tim Paterson- Brown, David Sumner and Allan Rowley collectively purchased 310,500 ordinary shares of the Company at an average price of 42 pence per share.

[crosswire] 19/5/2011 21:27

In comparison to an optical colonoscopy examination, a Virtual Colonoscopy has the benefits of:

(a) being much less invasive;

(b) has no requirement for intravenous sedation or pain medication; and


(c)requires no recovery time.

[crosswire] 19/5/2011 21:23

Floated at 110p 2007

"The clearance enables Medicsight to implement its US sales and marketing strategy, a primary objective in the development of the business since flotation."

"We look forward to the commercialisation of Medicsight ColonCAD in the United States through our network of advanced visualisation partners who are ready to deliver the ColonCAD solution to end users."

[ukmassy] 19/5/2011 20:31

Guys, what's your expectations for tomorrow? Another good day?

[imabastard] 19/5/2011 20:15

Crosswire .... 51 million free float .... exceedingly low .... good news.

[crosswire] 19/5/2011 18:45

Medicsight
SPECULATIVE BUY


14/08/2008



On flotation in June last year, cancer-screening software provider Medicsight was valued by the City at £170m. Now, one credit crunch and no real revenues later, the company is worth almost two-thirds less.

[crosswire] 19/5/2011 18:29

Shares Outstanding

155.53m



Free Float Only

51.31m



++++++++++++++++++++++++++++++++++++++++++++++++++++++++
Status and Trend Analysis

According to the short-term technicals, Medicsight Plc will continue its positive development to test the resistance area of 9.76. There is the possibility of a decline to the 4.78 low. Overall, we expect the stock to rise towards the test of a new 14.73 target.

[crosswire] 19/5/2011 18:18

Wall Street Journal

Medicsight Eyes Major Deals After FDA Clearance

LONDON (Dow Jones)--Medical software firm Medicsight PLC (MDST.LN) is in partnership talks with a number of major equipment manufacturers for its flagship product, and is hopeful of signing deals now that it has secured marketing approval from the U.S. Food and Drug Administration, the firm's finance director said Thursday.

[safman] 19/5/2011 18:16

I'm all for technology that is less invasive to patients, and you don't get more invasive when it comes to the colon issue... Medical imaging has gone from strength to strength and more accurate as the years have it..

The FDA approval is excellent for the company to get into the highly lucrative U.S market, but the company has a lot work to do and it will be in stages...

From a valuation perspective, it's very difficult to do so at this stage, but the market is most definitely there....

Good luck..

saffy..

[crosswire] 19/5/2011 18:16

Guardian

Finally Medicsight more than doubled - up 4.725p to 8.1p - as regulators cleared the way for its medical analysis software, primarily used to help diagnose colon cancer, to be sold and marketed in the US.

[crosswire] 19/5/2011 18:12

Evening Standard

Further down the pecking order, medical imaging company Medicsight shot up 2.6p to 6p.

American health watchdogs have given the green light to its technology which helps radiologists to look for abnormal tissue growth in patients' colons. But today's jump will only be a small comfort to long-term investors: the shares was changing hands for 25p at the start of 2009.

[crosswire] 19/5/2011 18:10

LONDON (Dow Jones)--Medicsight PLC (MDST.LN), a developer of Computer-Aided Detection and medical image analysis software said Thursday that the Medicsight ColonCAD API has received clearance from the U.S. Food and Drug Administration or FDA.

MAIN FACTS:

-The clearance enables Medicsight to implement its U.S sales and marketing strategy, a primary objective in the development of the business since flotation.

-Medicsight's ColonCAD is designed to assist radiologists during their review of CT colonography (CTC - also known as "Virtual Colonoscopy") images by automatically highlighting potential colorectal polyps (possible precursors to colorectal cancer) on the CT image.

-Shares at 0752 GMT up 2 pence, or 70.4%, at 6 pence, valuing the company at GBP8.94 million.

-By Razak Musah Baba, Dow Jones Newswires; 44-20-7842-9275; [e-mail]

[crosswire] 19/5/2011 18:08

Medicsight shares rise on US FDA clearance news

9:49 am by Andre Lamberti

Medicsight's ColonCAD is designed to assist radiologists during their review of CT colonography images

Shares in Medicsight PLC (LON:MDST) soared on news the US Food and Drug Administration (FDA) has cleared the Computer-Aided Detection (CAD) and medical image analysis software group to implement its US sales and marketing strategy.

The stock shot up in early deals and was still trading up more than 70 percent by midmorning at 5.75 pence.

Medicsight's ColonCAD is designed to assist radiologists during their review of CT colonography (CTC - also known as Virtual Colonoscopy) images by automatically highlighting potential colorectal polyps, possible precursors to colorectal cancer, on the CT image.

The FDA clearance was supported by a large clinical trial involving 15 radiologist readers who each reviewed 112 patient CT colonography cases both unassisted and assisted by ColonCAD.

Mediscsight chief executive Allan Rowley said: "We look forward to the commercialisation of Medicsight ColonCAD in the United States through our network of advanced visualisation partners who are ready to deliver the ColonCAD solution to end users.

[mikeja] 19/5/2011 17:35

Taking into account the delays and the fact that Japan is still awaited,perhaps£100m might be fairer,that is about 60p a share.

[mikeja] 19/5/2011 17:32

The last Edison note in 2009 gave an NPV for the co of £147m.